Nanoco to Present at Upcoming Industry Conferences
18.2.2025 12:00:00 CET | Business Wire | Press release
Nanoco Group PLC (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other advanced nanomaterials, is ramping up its commercial engagement as it transitions to scaled production. Over the coming months the company will be attending several key industry events to showcase its technology, connect with its customers and development partners, and to accelerate adoption of its solutions.
In March, Nanoco Founder and CTO Dr. Nigel Pickett will speak at the Society for Information Display (SID) UK Chapter meeting in London. His presentation, “Molecular Seeding Technology for Display Applications and Beyond,” will explain how Nanoco’s technology can enhance micro-LED and other displays, making them more efficient and cost-effective for mass production. As the industry moves toward brighter, more energy-efficient screens, Nanoco is working with partners to bring its technology into commercial products.
Later that month Nanoco will attend and sponsor Image Sensors Europe, a major industry gathering of over 250 vision technology professionals. The team will engage with potential customers and partners, highlighting how Nanoco’s quantum dot-based imaging solutions are unlocking new possibilities across several industries.
In April, Nanoco will be presenting its latest results on Image Sensors at SPIE Defense + Commercial Sensing conference in Orlando, Florida. The presentation, “Molecular Seeding Technology: Enabling Sensing Applications of the Future,” will highlight how Nanoco’s technology enables the production of Quantum Dots at scale making high-performance infrared image sensors more affordable and available. These sensors are in growing demand and Nanoco is positioning itself as a key player in that industry.
Nigel Pickett, Ph.D., the founder and CTO of Nanoco, said:
"Molecular seeding technology is our foundational IP for high volume quantum dot production. It allows us to manufacture high-quality materials efficiently, meeting the strict demands of the electronics industry. We believe it is the only feasible method to manufacture Quantum Dots at scale. This technology has already played a pivotal role in advancing display technologies, and we are now seeing the same potential in quantum dot enabled sensing applications where Nanoco has the largest product portfolio.
Dmitry Shashkov, Ph.D., CEO of Nanoco, said:
"We are excited to present our latest achievements to the industry and take the next steps to align the business with commercial execution. These industry events are not just about presenting technology—they are about building relationships with partners and customers who will be instrumental in bringing QD Image Sensors into mass adoption. We at Nanoco see the next 1-2 years as a major inflection point for the industry, as low-cost, wafer-scale production processes will bring QD Image Sensors to a wide variety of applications, including consumer, automotive, industrial and defense sectors."
About Nanoco Group plc
Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium-free quantum dots (CFQD®) and other nanomaterials for use in the electronics industry. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build a world-class, patent-protected IP portfolio alongside its existing scaled-up production facilities for commercial orders.
For further information, please visit: www.nanocotechnologies.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218331567/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom